Farmaceutica REMEDIA S.A.
STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)
31.12.2023 | 31.12.2022 | ||
Net turnover | NOTE 4 | 593.358.927 | 535.850.640 |
Income from the sale of goods | 589.976.173 | 530.960.392 | |
Commercial discounts granted | -2.202.020 | -2.799.654 | |
Income from services provided and rents | 5.584.773 | 7.689.902 | |
Other operating income | 4.921.303 | 3.350.123 | |
OPERATING INCOME - TOTAL | 598.280.230 | 539.200.763 | |
Expenses with materials | NOTE 5 | 547.527.853 | 491.419.460 |
Expenses regarding goods | 555.927.973 | 495.526.556 | |
Commercial discounts received | -11.009.494 | -8.770.460 | |
Expenses with raw materials and consumables | 1.539.879 | 3.485.778 | |
Other expenses with materials (inventory objects) | 138.925 | 142.418 | |
Energy and water expenses | 930.570 | 1.035.168 | |
Expenses with personnel | NOTE 6 | 20.619.788 | 22.132.735 |
Salaries and allowances | 17.707.353 | 19.309.357 | |
Expenses with insurance and social protection | 886.176 | 903.217 | |
Other personnel expenses | 2.026.259 | 1.920.161 | |
Amortisations and provisions | 5.548.329 | 4.067.397 | |
Amortisations | 5.058.187 | 4.016.528 | |
Net provisions | 425.051 | -279.307 | |
Losses from receivables | 65.092 | 330.175 | |
Other operating expenses | NOTE 7 | 16.428.569 | 14.835.225 |
Expenses on external services | 12.592.973 | 10.711.430 | |
Expenses with other taxes, charges and assimilated payments | 2.500.207 | 1.934.291 | |
Other expenses | 1.335.389 | 2.189.505 | |
OPERATING EXPENSES - TOTAL | 590.124.539 | 532.454.817 | |
OPERATING RESULT | 8.155.691 | 6.745.946 | |
Financial income | NOTE 8 | 1.298.237 | 844.833 |
Interest income | 869.372 | 386.605 | |
Income from exchange rate differences | 102.132 | 99.868 | |
Income from dividends | 68.305 | 79.826 | |
Advance payment discounts | 258.428 | 257.985 | |
Other financial income | 20.549 | ||
Financial expenses | NOTE 8 | 545.353 | 532.927 |
Expenses regarding interests leasing | 53.571 | 99.822 | |
Operational leasing interests | 67.988 | 62.476 | |
Expenses due to exchange rate differences | 143.570 | 179.995 | |
Discounts received in advance | 0 | 172.434 | |
Other financial expenses | 0 | 18.200 | |
Other financial expenses - share of the loss from investments accounted for using the equity method | 280.224 | ||
FINANCIAL RESULT | 752.884 | 311.906 | |
TOTAL INCOME | 599.578.467 | 540.045.595 | |
TOTAL EXPENSES | 590.669.892 | 532.987.744 | |
GROSS RESULT | NOTE 9 | 8.908.575 | 7.057.852 |
Profit tax | 1.706.927 | 1.248.719 | |
TOTAL NET PROFIT of which distributable | 7.201.648 | 5.809.133 | |
Shareholders of the company | 7.201.648 | 5.809.133 | |
Minority interest | |||
Other elements of comprehensive income | |||
Revaluation of tangible assets | |||
Tax related to other elements of comprehensive income | |||
Minority interest | |||
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of which attributable: | 7.201.648 | 5.809.133 | |
Shareholders of the company | 7.201.648 | 5.809.133 | |
Minority interest | |||
Earnings per share (in Lei) | |||
- basic | 0,0754 | 0,0608 | |
- diluted | 0,0754 | 0,0608 |
* retreated according to IFRS 16
Chairman of the Board of Administrators "TARUS" - Valentin Norbert TARUS e.U.
by representative
Valentin - Norbert TARUS
Farmaceutica REMEDIA S.A.
STATEMENT OF FINANCIAL POSITION - consolidated (Lei)
31.12.2023 | 31.12.2022 | ||
ASSETS | |||
Fixed assets | 46.768.058 | 44.484.546 | |
Tangible assets | NOTE 10 | 27.159.628 | 24.760.379 |
Real estate investments | 16.364.407 | 16.545.703 | |
Assets related to the rights of use of leased assets | 1.939.283 | 1.002.094 | |
Software licences | NOTE 11 | 553.105 | 109.054 |
Pharmacy licences | NOTE 11 | 628.255 | 689.200 |
Participations held in group companies | NOTE 12 | 0 | 588.620 |
Participations held in companies outside the group | NOTE 12 | 5.916 | 5.916 |
Investments in jointly controlled entities accounted for using the equity method | 21.509 | ||
Deposits and guarantees paid | NOTE 12 | 95.955 | 783.580 |
Current assets | 268.433.018 | 240.890.648 | |
Stocks | NOTE 13 | 44.334.576 | 46.262.314 |
Trade receivables | NOTE 14 | 184.264.742 | 173.704.309 |
Other receivables | 5.335.665 | 2.840.680 | |
Cash and cash equivalents | NOTE 15 | 34.498.036 | 18.083.345 |
Accrued expenses | 560.447 | 829.696 | |
TOTAL ASSETS | 315.761.523 | 286.204.891 | |
EQUITIES AND DEBTS | |||
Equities | 70.859.551 | 68.433.434 | |
Share capital | NOTE 16 | 9.860.311 | 9.860.311 |
Share premiums | 757.485 | 757.485 | |
Reserves | NOTE 17 | 40.960.056 | 39.953.756 |
Current result | 7.201.648 | 5.809.133 | |
Retained earnings | NOTE 19 | 15.231.167 | 12.477.605 |
Retained earnings - retreatment | -890.120 | -312.229 | |
Profit distribution | 0 | 0 | |
Own shares | NOTE 21 | -2.260.996 | -112.628 |
Long-term debts | 5.447.865 | 3.175.842 | |
Debts from long term leasing | NOTE 22 | 1.199.792 | |
Debts from operational leasing | |||
Provisions | NOTE 23 | ||
Debts with deferred income tax | 4.248.073 | 3.175.842 | |
Current debts | 239.454.107 | 214.595.615 | |
Bank loans | NOTE 24 | ||
Debts from financial leasing | 421.384 | ||
Debts from operational leasing | 932.428 | 777.861 | |
Suppliers and other similar debts | 235.343.070 | 209.969.435 | |
Provisions | 440.784 | 217.307 | |
Current tax debts | 325.137 | 155.049 | |
Other short-term debts | NOTE 25 | 2.412.688 | 3.054.580 |
Total debts | 244.901.972 | 217.771.457 | |
TOTAL EQUITIES AND DEBTS | 315.761.523 | 286.204.891 |
* retreated according to IFRS 16
Chairman of the Board of Administrators "TARUS" - Valentin Norbert TARUS e.U.
by representative
Valentin - Norbert TARUS
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Farmaceutica REMEDIA SA published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 21:42:20 UTC.